Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Reddit Post Question

<< Previous

Bullboard Posts

Next >>

Comment by qwerty22on Mar 01, 2021 8:49pm

92 Views

Post# 32691879

RE:RE:RE:Reddit Post Question

Novo Nordisk also sponsored a small study in non-hiv young NAFLD adults treated with recombinant Growth Hormone and showed liver fat reduction.
https://onlinelibrary.wiley.com/doi/abs/10.1111/cen.14344

He's wrong to think this is HIV specific.The GH effect is true across numerous metabolically impaired cohorts (obese, GH deficient)
My personal view. He's right to think if you want to fully derisk the Ph2 stage then THTX should do a Ph2b in non-HIV F2/F3 NASH patients but that is not necessarily the best path to market given where they are right now. There is a Stanley study (the lead of the NN study) reading out in late 2022 of non-HIV NAFLD patients treated with Tesamorelin.